

MLPCARE



MLP SAĞLIK HİZMETLERİ A.Ş.

**Interim Report of the Board of Directors for the Nine Months Ended
as of September 30, 2021**

Table of Contents

1. Overview:	1
2. Corporate Structure:	1
2.1 Shareholder Structure:	1
2.2 Major Participations (as of September 30, 2021):	1
2.3 Organizational Chart:	2
3. Developments During the Period:	2
4. Corporate Governance Compliance Report:	3
4.1 Corporate Governance Principles Compliance Report:	3
4.2 Strategy and Investor Relations Department:	3
4.2.1 Stock Information	4
4.3 The Structure and the Formation of the Board of Directors:	5
4.4 Working Principles of the Board of Directors:	5
4.5 The Number, the Structure and the Independence of the Committees within the Board of Directors:	5
5. 9M 2021 Earnings Release	7

1. Overview:

Founded in 1993, MLP Sağlık Hizmetleri A.Ş. (“MLP Care”, “the Group” or “the Company”) is the largest Turkish private healthcare group, with 30 hospitals located in 15 Turkish cities. MLP Care includes the Medical Park and Liv Hospital brands as well as VM Medical Park concept, with hospitals that span the country, from Bursa and Elazığ to Trabzon and Antalya.

2. Corporate Structure:

2.1 Shareholder Structure:

Shareholder Name	Ownership Interest (%)	Ownership Interest (thousand TL)
Publicly Traded (*)	35.01%	72,833
Lightyear Healthcare B.V.	30.69%	63,844
Hujori Financieringen B.V.	3.98%	8,287
Sancak İnşaat Turizm Nakliyat ve Dış Ticaret A.Ş.	15.35%	31,943
Usta Group - Elbaşı Group	14.97%	31,130
Total	100.00%	208,037


(*) The shareholders of the Company purchased 6,827 thousand shares from the publicly traded portion of the capital. Distribution of the shares purchased is as follows; 3,224 thousand shares representing 4.43% of the publicly traded portion were purchased by Lightyear Healthcare B.V., 1,613 thousand shares representing 2.21% of the publicly traded portion of the capital were purchased by Sancak İnşaat, 943 thousand shares representing 1.29% of the publicly traded portion of the capital were purchased by Muharrem Usta, 418 thousand shares representing 0.57% of the publicly traded portion of the capital were purchased by Hujori Financieringen B.V., 314 thousand shares representing 0.43% of the publicly traded portion of the capital were purchased by Adem Elbaşı and lastly other shareholders purchased 314 thousand shares representing 0.43% of the publicly traded portion. 1,613 thousand shares purchased by Sancak İnşaat from the publicly traded portion were sold on September 24, 2018. 126 thousand shares purchased by İzzet Usta and 18 thousand shares purchased by Adem Elbaşı from the publicly traded portion were sold.

2.2 Major Participations (as of September 30, 2021):

Trade Name	Proportion of ownership and voting power held(%)
Sentez Sağlık Hizmetleri A.Ş. (“Sentez Hastaneleri”)	56.00%
Temar Tokat Manyetik Rezonans Sağlık Hizmetleri ve Turizm A.Ş. (“Tokat Hastanesi”)	58.84%
Samsun Medikal Grup Özel Sağlık Hizmetleri A.Ş. (“Samsun Hastanesi”)	80.00%
Özel Samsun Medikal Tıp Merkezi ve Sağlık Hizmetleri Tic. Ltd. Şti. (“Samsun Tıp Merkezi”)	100.00%
MS Sağlık Hizmetleri Ticaret A.Ş. (“MS Sağlık”)	75.00%
Mediplaza Sağlık Hizmetleri Ticaret A.Ş. (“Mediplaza”)	75.00%
MA Group Sağlık ve Danışmanlık Hizmetleri Ticaret A.Ş. (“MA Grup”)	51.00%

BTR Sağlık Hizmetleri A.Ş. ("BTR Sağlık")	100.00%
İstanbul Meditime Sağlık Hizmetleri Ticaret Ltd. Şti. ("Meditime Sağlık")	100.00%
MLP Gaziantep Sağlık Hizmetleri Anonim Şirketi ("MLP Gaziantep Sağlık")	60.00%
Sotte Sağlık Temizlik Yemek Medikal Turizm İnşaat San. ve Tic. A.Ş. ("Sotte Sağlık Temizlik Yemek")	100.00%
Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. ("Kuzey")	100.00%
Artimed Medikal Sanayi ve Ticaret Ltd. Şti. ("Artimed")	100.00%
21. Yüzyıl Anadolu Vakfı ("21.Yüzyıl Anadolu Vakfı")	100.00%
BTN Sigorta Aracılık Hizmetleri A.Ş. ("BTN Sigorta")	100.00%
Endmed Endüstri Medikal Malzeme Cihazlar San. Tic. Ltd. Şti. ve Kuzey Medikal Pazarlama İnşaat Taşımacılık San. ve Tic. Ltd. Şti. İş Ortaklığı ("Kuzey Hastaneler Birliği" ya da "KHB")	99.90%
BTN Asistans Sağlık Hizmetleri A.Ş. ("BTN Asistans")	100.00%

2.3 Organizational Chart:



¹ Independent directorate reporting to the Board

3. Developments During the Period:

– Announcement Regarding The Directors and Officers Liability Insurance (October 11, 2021 Dated Announcement)

MLP Sağlık Hizmetleri A.Ş. is covered by Directors and Officers Liability Insurance in accordance with article 4.2.8 of Corporate Governance Principles published by the Capital Markets Board of Turkey stating that "Any damage that may be caused by the members of the board of directors during the discharge of their duties is insured for an amount exceeding 25% of the company's capital". The insurance limit is USD 10,000,000 and covers the period between September 23, 2021 and September 23, 2022.

– Institutional Investor 2021

MLP Sağlık Hizmetleri (MLP Care), the leading hospital group of Turkey with Medical Park and Liv Hospital brands has been awarded by Institutional Investor for its successful investor relations practices.

MLP Care awarded as the “Best Investor Relations Program” amongst Emerging EMEA Healthcare & Pharmaceuticals category. MLP Care executives, the Chairman and CEO Dr. Muharrem Usta, CFO Burcu Öztürk, and Strategy and Investor Relations Director Dr. Deniz Can Yücel were awarded as the “Best CEO”, “Best CFO” and “Best IR Professional”, respectively.

MLP Care also awarded as the “Best Investor Relations Program” amongst BIST All category. MLP Care executives, CFO Burcu Öztürk and Strategy and Investor Relations Director Dr. Deniz Can Yücel were awarded as the “Best CFO” and “Best IR Professional”, respectively.

4. Corporate Governance Compliance Report:

4.1 Corporate Governance Principles Compliance Report:

In accordance with the resolution No. 2/49 made by the Capital Markets Board of the Prime Ministry of the Republic of Turkey on January 10, 2019, the Company disclosed the “Compliance Report Format (CRF)” which indicates the compliance status of the Company with the principles of voluntary compliance and the “Corporate Governance Information Form (CGIF)” which indicates the existing corporate governance practices, on the Public Disclosure Platform (KAP) in March 11, 2021. The aforementioned announcements can be reached through <https://www.kap.org.tr/en/Bildirim/917642> and <https://www.kap.org.tr/en/Bildirim/917644> links, respectively.

4.2 Strategy and Investor Relations Department:

Updated information regarding the personnel working at the Company’s Strategy and Investor Relations Department is given below. Strategy and Investor Relations Director Dr. Deniz Can Yücel works fulltime and directly reports to Muharrem Usta, the Chairman of the Board of Directors and CEO.

Information regarding the personnel working at the Company’s Strategy and Investor Relations Department:

Dr. Deniz Can Yücel

Strategy and Investor Relations Director

Tel: 0 212 227 55 55

Fax: 0 212 227 23 28

e-mail: deniz.yucel@mlpcare.com

Licenses: CMB Advanced and CMB Corporate Governance Rating Specialist Licenses

Turgut Yılmaz

Strategy and Investor Relations Associate Director

Tel: 0 212 227 55 55

Fax: 0 212 227 23 28

e-mail: turgut.yilmaz@mlpcare.com

During the first nine months period of 2021, in order to inform shareholders and investors IR Department attended a total of 157 meetings, including domestic and abroad roadshows and conferences, which were organized with both domestic and foreign corporate and individual investors, shareholders and analysts to discuss about Company's operational results, performance and other developments.

4.2.1 Stock Information

Number of Shares: 208,037,202 (each with a nominal value of TL 1.00 per share)


Date of IPO: February 13, 2018

Public: 35.01% (TFRS Report)

Stock Performance in 9M 2021:

January 1 – September 30, 2021	Lowest	Highest	Average	September 30, 2021
Stock Price (TL)	19.87	27.48	23.53	27.48
Market Value (million USD)	518	756	606	643

Stock Performance:



Independent Auditor:

In our General Assembly Meeting held on April 15, 2021, **PwC Bağımsız Denetim ve Serbest Muhasebeci Mali Müşavirlik A.Ş.** has been selected as the independent auditor to audit our Company's financial reports for the year 2021 accounting period and to fulfill all other obligations required for the auditors by Turkish Commercial Code numbered 6102 and Capital Markets Law numbered 6362 and related regulations.

4.3 The Structure and the Formation of the Board of Directors:

Company's Board of Directors comprises of six members:

- Muharrem Usta – Chairman and CEO
- Seymur Tarı – Vice Chairman
- Hatice Hale Özsoy Bıyıklı – Board Member
- Haydar Sancak – Board Member
- Meral Kurdaş – Independent Board Member
- Tayfun Bayazıt – Independent Board Member

4.4 Working Principles of the Board of Directors:

It's aimed to carry out the duties of the Board in accordance with the Corporate Governance Principles in a transparent, accountable, fair, and responsible manner. In this context, in line with the Corporate Governance Principles, the Board meetings are conducted regularly (at least four times a year) in a way that it can efficiently carry out its duties. The members of the Board also hold meetings whenever it is necessary.

Board members aim attending every meeting and present their opinions. When there are dissenting opinions on reasonable and detailed grounds regarding the questions asked or different opinions expressed by Board members, these are recorded in the meeting minutes.

4.5 The Number, the Structure and the Independence of the Committees within the Board of Directors:

In its meeting held on April 30, 2021, the Board of Directors resolved to;

- 1) Establish a Nomination and Remuneration Committee,
- 2) Establish the Nomination and Remuneration Committee charter, revise the charters of Audit Committee, Corporate Governance Committee, and Early Detection of Risk Committee, and bring them to the attention of stakeholders on the Company website,
- 3) Appoint the members of the Committees in accordance with the provisions of the Corporate Governance Communiqué numbered II-17.1 of the Capital Markets Board,
 - a) Appoint Tayfun Bayazıt as the Chairman of the Audit Committee; Meral Kurdaş as the member of the Audit Committee,
 - b) Appoint Tayfun Bayazıt as the Chairman of the Corporate Governance Committee and Meral Kurdaş, Hatice Hale Özsoy Bıyıklı, and Deniz Can Yücel as the members of the Corporate Governance Committee,

- c) Appoint Meral Kurdaş as the Chairman of the Early Detection of Risk Committee and Tayfun Bayazıt and Hatice Hale Özsoy Bıyıklı as the members of the Early Detection of Risk Committee.
- d) Appoint Meral Kurdaş as the Chairman of the Nomination and Remuneration Committee and Tayfun Bayazıt and Hatice Hale Özsoy Bıyıklı as the members of the Nomination and Remuneration Committee.

The resumes of the Committee Members and the Committee Charters, determining the principles of operation for each Committee, are available at our website "<http://investor.mlpcare.com/en/>".

In 2021, the Audit Committee and the Corporate Governance Committee held four meetings on March 1, April 30, August 2, and November 2, 2021. On the other hand, the Early Detection of Risk Committee held five meetings on January 28, March 1, April 30, August 2, and November 2, 2021. The Nomination and Remuneration Committee held one meeting on April 30, 2021. In the following period, they will continue to meet and perform their duties as often as their charters require.

5. 9M 2021 Earnings Release

Summary Financials

(TL million)	9M 2021	9M 2020	Change	Q3 2021	Q3 2020	Change
Revenues	4,040	2,814	43.6%	1,498	1,075	39.3%
EBITDA¹	1,068	766	39.5%	392	312	26.0%
EBITDA margin (%)	26.4%	27.2%	(77bps)	26.2%	29.0%	(276bps)
EBITDA¹ (w/o fx impact)²	1,029	693	48.5%	396	279	42.2%
EBITDA margin (%)	25.5%	24.6%	84bps	26.4%	25.9%	55bps
Net Profit/(Loss) Before Tax	335	89	276.9%	147	25	497.0%
Net Profit/(Loss)	215	52	315.3%	41	13	224.4%
Net Profit/(Loss) (allocated to equity holders of the parent)	165	23	610.3%	18	(4)	n.m.
Free Cash Flow	851	580	46.9%	335	278	20.7%
Capital Expenditure	245	108	125.8%	76	52	46.7%
Net Debt³ (including TFRS 16 impact)	1,967	2,088	(5.8%)	1,967	2,088	(5.8%)

¹ Adj. EBITDA is based on reported EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) adjusted for one-time (income) / expenses, net and non-cash GAAP provision expenses

² Without fx impact of other income/expenses from operating activities

³ Including obligations under operational leases related to TFRS 16

Financial Highlights

- ✓ In Q3 2021, total revenues increased by 39% to TL 1,498 million (Q3 2020: TL 1,075 million). The continued robust uptick in domestic patient revenues quarter-on-quarter and the accelerated recovery of foreign medical tourism business have been the main drivers for the strong performance. Overall, 9M 2021 revenues increased by 44% to TL 4,040 million (9M 2020: TL 2,814 million).
- ✓ In Q3 2021, the adj. EBITDA (w/o fx impact) increased by 42% to TL 396 million, while adj. EBITDA (w/o fx impact) margin increased by 55 bps at 26.4%. In 9M 2021, the adj. EBITDA (w/o fx impact) increased by 48% to TL 1,029 million, while the adj. EBITDA (w/o fx impact) margin increased by 84 bps to 25.5%.
- ✓ In Q3 2021, net profit increased by 224.4% to TL 41 (Q3 2020: TL 13 million). It is important to note that this increase is after the one-off deferred tax expense adjustment of TL 69 million related to the tax base increase. Accordingly, net profit in 9M 2021 increased to TL 215 million (9M 2020: TL 52 million). Net profit allocated to equity holders of the parent was TL 18 million in Q3 2021 (Q3 2020: TL 4 million loss). Rapid recovery of revenues compared to previous year, effective cost optimization, and reduction of financial expenses (realized after closure of FX open position in financial debt in February 2021) have supported the net profit increase.
- ✓ The net debt/adj. EBITDA ratio was successfully decreased to 1.5x in 9M 2021 from 2.0x in 2020 on the back of strong EBITDA and cash generation performance. Net debt decreased by TL 150 million compared to 2020. This decrease was realized despite the additional debt (financial leasing and obligations under operational leases related to TFRS 16) of TL 174 million related to Liv Hospital Vadistanbul which was opened in May 2021.

Operating Highlights

- ✓ In Q3 2021, private medical insurance revenue went up by 68% especially driven by the strong growth of the top-up insurance. This high growth momentum was supported by the increase in demand for private medical insurance after the pandemic.

- ✓ Foreign Medical Tourism (FMT) revenue grew by 127% in Q3 2021 due to the low base effect triggered by the 22% contraction in Q3 2020 and the gradual openings of international flights this year.
- ✓ There has been an upward revision in the SSI price tariff effective from June 1, 2021.
- ✓ Liv Hospital Vadi Istanbul has started accepting patients on May 24, 2021 in Istanbul, Sarıyer with a capacity of 125 beds. In addition to domestic patients, this hospital will serve foreign patients from European and Balkan countries, the Middle East and Arab countries.

Dr. Muharrem Usta, Chairman and Chief Executive Officer of MLP Care, commented:

“COVID-19 pandemic, which started in our country in March 2020, has created an unprecedented health and economic emergency globally. Throughout this period we worked with great devotion as we have the largest established footprint amongst the private healthcare providers in Turkey and bear a huge responsibility to our community. We continued to improve our operational performance on the back of diligent cost discipline, strengthened our cash position, and reduced our leverage ratio. We eliminated the impact of FX volatility from our financials by converting our FX denominated loans into TL and closing our open FX position against any potential macro headwinds.

The pent-up demand for health services, has been strong and resulted in high domestic and international patient traffic this year. In our group, digitalization projects continue at a full speed. Through our digital personnel planning system in all hospitals, we optimize staff allocation, and personnel working hours. With Robotic Process Automation (RPA), we aim to fully automate all invoice processes, thus directing staff time to higher value-added jobs. We aim to complete our digital supply chain program and deploy in all our hospitals next year. With this project, we will provide better inventory management and create additional cost savings. We believe that these efforts will make a positive contribution to our efficiency and therefore profitability in the future.

Revenues

	9M 2021	9M 2020	Change	Q3 2021	Q3 2020	Change
Total Revenues (TL million)	4,040	2,814	43.6%	1,498	1,075	39.3%
Domestic Patient Revenues	3,457	2,395	44.4%	1,232	916	34.6%
Inpatient Revenues	2,033	1,464	38.9%	706	538	31.1%
Outpatient Revenues	1,424	931	53.0%	527	378	39.4%
Foreign Medical Tourism Revenues	460	226	103.1%	207	91	126.8%
Other Ancillary Business	122	193	(36.5%)	58	68	(14.6%)

Domestic Patient Revenues: Revenues from domestic patients increased by 34.6% in Q3 2021 on the back of strong growth in both inpatient and outpatient revenues. This growth was driven by the improvement in number of patients since the beginning of the year and the average price increase related to SUT price revisions in June 2021. Revenues from domestic patients increased by 44.4% in 9M 2021. This high growth was additionally supported by low base effect as a result of 3.8% contraction in domestic revenues in Q2 2020 due to pandemic related restrictions.

The inpatient revenues grew by 31.1% in Q3 2021, 38.9% in 9M 2021. The outpatient revenues grew by 39.4% in Q3 2021, 53.0% in 9M 2021.

Foreign Medical Tourism (FMT) Revenues: FMT revenues had contracted by 67.0% in Q2 2020 and 21.9% in Q3 2020 due to the flight restrictions kicked off during the pandemic. On the other hand, FMT revenues was up by 126.8% in Q3 2021 and 103.1% in 9M 2021, as the vaccination speed accelerated both in Turkey and in many of the countries and the number of traveling passengers increased. In Q3 2021, FMT revenues increased by 43.9% compared to Q2 2021. FMT revenues as a percentage of the total revenues was 13.8% in Q3 2021 and 11.4% in 9M 2021.

Other Ancillary Business: Revenues from other ancillary business decreased by 14.6% in Q3 2021 and 36.5% in 9M 2021 due to voluntary non-renewal of the tender for the laboratory business in line with the strategy to focus on core business. Laboratory business revenues decreased by 82.9% to TL 7 million in Q3 2021, by 78.0% to TL 25 million in 9M 2021 (Q3 2020: TL 38 million, 9M 2020: TL 114 million).

On the other hand, management consultancy revenues from university hospitals increased by 53.8% to TL 24 million in Q3 2021, by 64.3% to TL 75 million in 9M 2021 (Currently, we have 6 university hospitals, of which 3 have management service contracts with us).

Cost of Service and Expenses (Including Hospitals and Ancillary Business)

	9M 2021	9M 2020	Change (bps)	Q3 2021	Q3 2020	Change (bps)
(% of Revenues)	73.6%	72.8%	77	73.8%	71.0%	276
Material	18.5%	22.4%	(395)	17.2%	22.2%	(496)
Doctor	21.9%	20.6%	135	21.3%	20.7%	64
Personnel	16.3%	16.5%	(15)	16.3%	15.9%	38
Rent	0.9%	0.9%	(2)	0.9%	0.7%	24
Outso. Serv. Purch.	8.0%	7.2%	78	7.2%	7.2%	2
All other exp.	8.0%	5.2%	276	10.9%	4.4%	643

Material consumption as a percentage of total revenue decreased by 496 bps in Q3 2021 and by 395 bps in 9M 2021 due to decrease in the share of other ancillary laboratory business, which has a high cost base and increase in inpatient unit prices.

Doctor costs as a percentage of total revenue increased by 64 bps in Q3 2021 and by 135 bps in 9M 2021. The increase is due to the new hospital opening in Q2 2021, hospital mix change, and increased percentage of hospital revenue in total revenue in line with contraction of the ancillary business revenue.

Personnel expenses as a percentage of total revenue decreased by 15 bps to 16.3% in 9M 2021 due to the strong revenue growth. On the other hand, this ratio in Q3 2021 was up by 38 bps to 16.3% due to the utilization of Short-time Work Program subsidy in Q3 2020 for more personnel, personnel salary adjustments, and new hospital openings.

Outsourced services purchases that consists of laboratory, imaging, cleaning, catering, security expenses increased by 2 bps to 7.2% in Q3 2021 and by 78 bps to 8.0% in 9M 2021 as percentage of the total revenue due to increased volume of the outsourced PCR test service expenses.

All other expenses (energy, foreign and domestic marketing expenses etc.) increased by 643 bps to 10.9% in Q3 2021 and by 276 bps to 8.0% in 9M 2021 primarily due to lower operational FX income and increase in the marketing expenses related to FMT revenues.

EBITDA

The adj. EBITDA number increased by 26.0% to TL 392 million in Q3 2021 on the back of strong operational performance and cost saving measures. Adj. EBITDA margin decreased by 276 bps to 26.2%. This decrease was driven primarily by the decreasing effect of operational FX income on total expenses (Q3 2021: 331 bps decrease) and increase in the marketing expenses related to FMT revenues (Q3 2021: 121 bps decrease).

The adj. EBITDA number increased by 39.5% to TL 1.068 million in 9M 2021. On the other hand, adj. EBITDA margin decreased by 77 bps to 26.4% due to decreased effect of operational FX income in total cost.

In Q3 2021, the adj. EBITDA (w/o fx impact) number increased by 42.2% to TL 396 million, while adj. EBITDA (w/o fx impact) margin increased by 55 bps to 26.4%. In 9M 2021, the adj. EBITDA (w/o fx impact) increased by 48.5% to TL 1,029 million, while the adj. EBITDA (w/o fx impact) margin increased by 84 bps to 25.5%.

Cash Flow

The operating cash flow increased by 24.8% to TL 411 million in Q3 2021 and by 59.3% to TL 1.096 million in 9M 2021 (Q3 2020: TL 329 million, 9M 2020: TL 688 million). Thus, the operating cash flow/EBITDA ratio was at 104.7% in Q3 2021 and 102.6% in 9M 2021 (Q3 2020: 105.8%, 9M 2020: 89.8%).

Free cash flow increased by 20.7% to TL 335 million in Q3 2021 and by 46.9% to TL 851 million in 9M 2021 (Q3 2020: TL 278 million, 9M 2020: TL 580 million) due to the decrease in working capital requirements. Therefore, free cash flow/adj. EBITDA ratio was at 85.5% in Q3 2021 and 79.7% in 9M 2021 (Q3 2020: 89.2%, 9M 2020: 75.7%).

Maintenance-related capital expenditures as a percentage of revenue was at 3.5% in Q3 2021 and 2.6% in 9M 2021 (Q3 2020: 2.1%, 9M 2020: 2.0%). Total capital expenditures as a percentage of revenue increased to 5.0% in Q3 2021 and 6.1% in 9M 2021 due to the TL 75 million capital expenditure made in 2021 for VadiIstanbul (Q3 2020: 4.8%, 9M 2020: 3.9%).

Profit/(Loss) for the Period

Due to the strong operational performance and cost savings, a net profit of TL 41 million in Q3 2021 and TL 215 million in 9M 2021 was generated. In 9M 2020, a profit of TL 52 million was generated with the contribution of goodwill of TL 82 million recognized from the favourable acquisition of VM Medical Park Ankara Hospital and TL 33 million fixed asset sales revenue of Uşak Hospital exit. Despite this base effect, net profit increased by 224.4% in Q3 2021 and 315.3% in 9M 2021.

High operational performance and cost savings measures (operating profit increase Q3 2021: TL 70 million, 9M 2021: TL 237 million), decreased finance expenses due to mitigated foreign currency risk (finance expenses decrease Q3 2021: TL 85 million, 9M 2021: TL 124 million). Deferred tax expense, on the other hand, decreased the profit for the period increasing by TL 69 million in 3Q 2021 and TL 38 million in 9M 2021 due to the one-off write-off of 50% of the deductible losses of previous years due to tax base increase.

Net profit allocated to non-controlling interest was TL 23 million in Q3 2021 and TL 50 million in 9M 2021 due to profitable subsidiaries. Therefore, a net loss of TL 4 million allocated to equity holders of the parent in Q3 2020 turned to profit of TL 18 million in Q3 2021. In 9M 2021, net profit allocated to equity holders of the parent increased by 610.3% to TL 165 million (9M 2020: TL 23 million).

Borrowings and Indebtedness

Net Debt by Currency (TL million)	9M 2021	Vertical Percentage	2020	Vertical Percentage	Change
TL	1,282	65%	1,064	50%	20.5%
USD + Euro	(26)	(1%)	457	22%	n.m.
Total loan, financial leasing	1,256	64%	1,521	72%	(17.5%)
TL (TFRS 16)	635	32%	521	25%	21.8%
USD + Euro (TFRS 16)	76	4%	74	3%	2.8%
Total lease liabilities (TFRS16)	711	36%	595	28%	19.5%
Total net debt	1,967	100%	2,117	100%	(7.1%)

The net debt/adj. EBITDA ratio was down to 1.5x in 9M 2021 from 2.0x in 2020 on the back of strong operating performance.

In 9M 2021, net debt excluding obligations under operational leases related to TFRS 16 decreased by TL 266 million to TL 1,256 million (2020: TL 1,521 million).

Total net debt including obligations under operational leases related to TFRS 16 decreased by TL 150 million to TL 1,967 million (2020: TL 2,117 million). The decrease was realized despite the debt of TL 174 million (of that TL 62 million was financial leasing and TL 112 million was obligations under operational leases related to TFRS 16) related to Liv Hospital Vadistanbul opening.

Currency risk management

The Company has converted all of the debt service for EUR 46.5 million syndicated loans for the years 2022-2024 into TL at the CBRT buying rate on February 8, 2021. The Company maintained its fx denominated net debt long position of EUR 2.6 million in 9M 2021. Therefore, potential FX volatility will not impact company financials going forward. Along with its long term strategy, the Company created natural hedge in balance sheet through keeping cash and cash equivalents in EUR denominated terms in efforts to manage foreign currency risk, to reduce financial expenses and net debt/EBITDA ratio.

EBITDA RECONCILIATION

TL million	9M 2021	9M 2020	Q3 2021	Q3 2020
Net profit / (loss)	215	52	41	13
Tax (income) from operations	120	37	106	12
Depreciation and amortization of tangible and intangible fixed assets	238	188	84	62
Total interest expenses/(income) and fair value differences of derivative instruments	427	557	148	239
Net (gains) / losses from the disposal of tangible and intangible assets and income from negative goodwill	(3)	(117)	(0)	(32)
Reported EBITDA	997	717	379	294
Net one-off (gains) / losses	52	38	16	14
Non-cash GAAP provision expenses	19	11	(2)	4
Adjusted EBITDA	1,068	766	392	312
Adjusted EBITDA margin (%)	26.4%	27.2%	26.2%	29.0%
Foreign exchange gains/(losses) from operations	39	73	(4)	33
Adjusted EBITDA¹	1,029	693	396	279
Adjusted EBITDA margin (%)¹	25.5%	24.6%	26.4%	25.9%

¹ Adj. EBITDA and Adj. EBITDA margin without foreign exchange gains/(losses) from other income/(expenses) from operating activities

SUMMARY CONSOLIDATED INCOME STATEMENT

	Unaudited	Unaudited		Unaudited	Unaudited	
TL million	9M 2021	9M 2020	Change (%)	Q3 2021	Q3 2020	Change (%)
Revenues	4,040	2,814	43.6%	1,498	1,075	39.3%
Cost of service (-)	(2,969)	(2,150)	38.1%	(1,062)	(799)	33.0%
Gross profit	1,071	664	61.2%	435	277	57.4%
General administration expenses (-)	(314)	(181)	73.8%	(121)	(68)	77.1%
Other income from operations	277	366	(24.2%)	50	205	(75.4%)
Other expenses from operations (-)	(249)	(302)	(17.3%)	(58)	(176)	(67.2%)
Operating profit/(loss)	784	548	43.2%	307	238	29.4%
Income from investing activities	3	119	(97.7%)	0	34	(99.4%)
Expense from investing activities (-)	(0)	(2)	(94.8%)	(0)	(2)	(97.1%)
EBIT	787	664	18.4%	307	270	14.0%
<i>EBIT margin</i>	<i>19.5%</i>	<i>23.6%</i>	<i>(414bps)</i>	<i>20.5%</i>	<i>25.1%</i>	<i>(456bps)</i>
Interest expenses (-)	(429)	(331)	29.4%	(166)	(105)	58.3%
Net foreign exchange profit / (loss) (including hedging cost)	(23)	(244)	(90.6%)	5	(140)	n.m.
Net profit / (loss) before tax	335	89	276.9%	147	25	497.0%
Tax income / (expense) from operations	(120)	(37)	223.1%	(106)	(12)	782.8%
Net profit / (loss)	215	52	315.3%	41	13	224.4%
Net profit / (loss) non-controlling interest	50	29	75.8%	23	17	n.m.
Net profit / (loss) equity holders of the parent	165	23	610.3%	18	(4)	n.m.

SUMMARY CONSOLIDATED BALANCE SHEET

TL million	Unaudited September 30, 2021	Unaudited September 30, 2020	Audited December 31, 2020
Cash and cash equivalents	676	492	375
Trade receivables	1,359	1,115	1,155
Inventory	122	112	113
Short term other assets	537	479	542
Current assets	2,694	2,198	2,185
Tangible and intangible fixed assets	1,539	1,431	1,441
Right of use assets	383	250	257
Deferred tax assets	351	415	402
Long term other assets	341	243	287
Non-current assets	2,614	2,339	2,387
Total assets	5,308	4,537	4,572
Trade payables	1,315	905	987
Short term other liabilities	461	431	422
Short term financial liabilities (incl. financial and operational leases)	1,188	888	978
Current liabilities	2,964	2,224	2,387
Long term other liabilities	148	140	139
Deferred tax liabilities	187	187	184
Long term financial liabilities (incl. financial and operational leases)	1,456	1,705	1,514
Non-current liabilities	1,791	2,031	1,836
Shareholders' equity	436	245	282
Non-controlling interest	116	37	66
Equity	552	282	349
Total liabilities & equity	5,308	4,537	4,572